Administration of L-TC

Phase 3Small molecule

IInstitut de cancérologie Strasbourg Europe

Administration of L-TC is one of 79 small molecule programs targeting Glioblastoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlioblastomaActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

GlioblastomaPhase 3

Active, not recruiting

Soft Tissue SarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

514 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

161 2

Ceenu

AAzurity Pharmaceuticals

Phase 3

22 3

Gleevec

Novartis

Phase 3

2 4

Scemblix

Novartis

Phase 3

1 5

Cymbalta

Alnylam Pharmaceuticals

Phase 3

1 6

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 7

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

4 8

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Droxia

TTheravia

Phase 3

3 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 2Not yet recruiting

Soft Tissue Sarcoma

NCT06476704

Q4 2032

Phase 3Not yet recruiting

Glioblastoma

NCT06477939

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas

Not yet recruiting·IInstitut de cancérologie Strasbourg Europe·Phase 2·NCT06476704·42 enrolled

Glioblastoma1 trial

Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

Not yet recruiting·IInstitut de cancérologie Strasbourg Europe·Phase 3·NCT06477939·554 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Administration of L-TC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Administration of L-TC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Administration of L-TC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de cancérologie Strasbourg Europe company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInstitut de cancérologie Strasbourg Europe

Administration of L-TC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Q4 2032

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News